{"id":52687,"date":"2016-02-15T15:00:07","date_gmt":"2016-02-15T15:00:07","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=52687"},"modified":"2016-02-15T15:00:07","modified_gmt":"2016-02-15T15:00:07","slug":"fannin-innovation-studio-names-melissa-singh-principal","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fannin-innovation-studio-names-melissa-singh-principal_52687.html","title":{"rendered":"Fannin Innovation Studio Names Melissa Singh Principal"},"content":{"rendered":"<div style=\" width:250px; padding:8px 10px 10px 10px; float:right;\"><a href=\"http:\/\/www.getnews.info\/wp-content\/uploads\/2016\/02\/a1455558566.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"image\" src=\"http:\/\/www.getnews.info\/wp-content\/uploads\/2016\/02\/a1455558566.jpeg\" alt=\"\" width=\"225\" height=\"337\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\" style=\" font-weight:bold; font-style:italic;\">\n<div>&#8220;Melissa Singh, PhD, leads the R&#038;D activities for Avid Chemotherapeutics and ACF Pharmaceuticals&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">Life science commercialization company Fannin Innovation Studio (<a rel=\"nofollow\" href=\"http:\/\/www.FanninInnovation.com\">www.FanninInnovation.com<\/a>) today promoted its first entrepreneur fellow, biomedical scientist Melissa Singh, Ph.D., to principal.&nbsp; With this move, entrepreneur fellow Erol Bakkalbasi, M.Sc. has been named senior entrepreneur fellow.<\/p>\n<p style=\"text-align: justify;\">Singh earned her BS in Chemistry from the University of Maryland, PhD in Biomedical Science from University of Texas Health Science Center in Houston, and was a Ruth L. Kirschstein postdoctoral fellow at the University of Texas MD Anderson Cancer Center where she focused on the discovery of novel therapeutic strategies for patients with glioblastoma.<\/p>\n<p style=\"text-align: justify;\">Joining Fannin as an intern in June 2014, Singh was quickly promoted to entrepreneur fellow before being named company principal.&nbsp;<\/p>\n<p style=\"text-align: justify;\">In her role, she leads the research and development activities for Fannin portfolio companies Avid Chemotherapeutics, developing a nanoparticle therapeutic for hard-to-treat cancers; and ACF Pharmaceuticals, a collaboration between The University of Texas MD Anderson Cancer Center, Cayman Chemicals and Fannin to explore the potential of novel, small molecule anti-cancer agents.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;Melissa is a highly-talented leader who possesses both the scientific skill set and the management capabilities required to advance the development of our portfolio companies,&rdquo; said Dr. Atul Varadhachary, Managing Partner, Fannin.<\/p>\n<p style=\"text-align: justify;\">As principal, Singh will also be responsible for Fannin&rsquo;s intern \/ fellowship program and will serve as the liaison between Fannin and educational institutions and oversee overall program development.&nbsp; Since its launch, 75 interns have successfully completed the company&rsquo;s experiential learning program. Of those graduates, 41 percent are women.<\/p>\n<p style=\"text-align: justify;\">Following the same path as Singh, molecular biologist Bakkalbasi, a graduate of Rice University and Baylor College of Medicine, also started with Fannin as an intern before being promoted to fellow in 2015.&nbsp; Now as senior fellow, Bakkalbasi serves as the lead for portfolio company Exotect, which is investigating a novel molecular pathway that controls mucus overproduction in asthmatics.&nbsp; He also provides support to point-of-care diagnostic developer, BreviTest.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> Fannin Innovation Studio<br \/><strong>Contact Person:<\/strong> Anna Halvorson<br \/><strong>Email:<\/strong> anna@penmanpr.com<br \/><strong>Phone:<\/strong> 713.510.0500<br \/><strong>City:<\/strong> Houston<br \/><strong>State:<\/strong> Texas<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.FanninInnovation.com\" target=\"_blank\" rel=\"nofollow\">www.FanninInnovation.com<\/a><\/p>\n<p><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.FanninInnovation.com\" style=\"width:605px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=fannin-innovation-studio-names-melissa-singh-principal\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Melissa Singh, PhD, leads the R&#038;D activities for Avid Chemotherapeutics and ACF Pharmaceuticals&#8221; Life science commercialization company Fannin Innovation Studio (www.FanninInnovation.com) today promoted its first entrepreneur fellow, biomedical scientist Melissa Singh, Ph.D., to principal.&nbsp; With this move, entrepreneur fellow Erol &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/fannin-innovation-studio-names-melissa-singh-principal_52687.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-52687","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/52687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=52687"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/52687\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=52687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=52687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=52687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}